Pay-for-Delay Drug Deals Said to Be Target for Rule at FTC

The Federal Trade Commission is considering using its rule-making power to stop so-called pay-for-delay deals between brand-drug manufacturers and makers of generic medicines after failing to get judges or Congress to act, three people familiar with the process said.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.